Scarica l'app Stockscreener
396.04
1.00%
3.94
Dopo l'orario di chiusura:
396.04
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
Demand prompts Alnylam’s $250 million manufacturing expansion - The Pharma Letter
PeptiDream and Alnylam Announce Achievement of Key Milestone in siRNA Conjugate Discovery Collaboration Demonstrating Peptide-Ligand Mediated Targeted siRNA Delivery to Specific Extrahepatic Tissues - Yahoo Finance
Alnylam plans $250m investment in Norton manufacturing facility, US - Yahoo Finance
Alnylam to invest $250 million in expanding RNA drug manufacturing By Investing.com - Investing.com Nigeria
Alnylam launching $250 million biomanufacturing expansion in Norton - The Boston Globe
Alnylam's $250M Norton facility upgrade aims to slash need for 20 plants down to 2 - The Business Journals
Alnylam to Invest $250M in U.S. Manufacturing Expansion for RNAi Therapeutics - citybiz
Alnylam (ALNY) Advances Norton Facility with $250M Investment - GuruFocus
Alnylam Pharmaceuticals to Invest $250 Million on Enzymatic Ligation Manufacturing Platform - marketscreener.com
Alnylam to invest $250 million to add enzymatic ligation platform - marketscreener.com
Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics - Business Wire
Sanders Morris Harris LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Announces Health Canada Approval of AMVUTTRA® (vutrisiran), the First and Only RNAi Therapeutic for the Treatment of Cardiomyopathy in Adult Patients with ATTR Amyloidosis - BioSpace
Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions - MSN
Alnylam announces Health Canada approval of Amvuttra® - marketscreener.com
Alnylam Pharmaceuticals (ALNY) Stock Price, Quote, News & History - Benzinga
Gene Therapy Market to Reach US$ 35.91 Billion by 2033 at 23.1% - openPR.com
Is Alnylam Entering A Corrective Phase After A Strong Run? - Sahm
Assessing Alnylam Pharmaceuticals’ (ALNY) Valuation After Its Inclusion in the Nasdaq 100 Index - Yahoo Finance
Is Alnylam (ALNY) Using Nasdaq 100 Inclusion To Quietly Redefine Its Capital Allocation Playbook? - simplywall.st
Alnylam Pharmaceuticals (ALNY) Rating Maintained, Price Target L - GuruFocus
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Cut to $351.00 by Analysts at Leerink Partners - MarketBeat
Alnylam, Seagate among six stocks added to Nasdaq-100 in annual rebalance - MSN
Peptidream reveals milestone in Alnylam collaboration - BioWorld MedTech
Liontrust Investment Partners LLP Cuts Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
NASDAQ adding Alnylam, Ferrovial, Insmed, Monolithic Power at open on 12/22 - MSN
Holocene Advisors LP Invests $194.62 Million in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
China Universal Asset Management Co. Ltd. Trims Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
A look at Alnylam Pharmaceuticals (ALNY) valuation after Nasdaq 100 inclusion and convertible notes repurchase - simplywall.st
Alnylam Pharmaceuticals: Challenges In The TTR Space And Few Late-Stage Catalysts Are A Concern - Seeking Alpha
Seagate, Alnylam among six companies set to join Nasdaq 100 - MSN
Alnylam (ALNY) and Seagate (STX) Join Nasdaq 100 Index - GuruFocus
Gilder Gagnon Howe & Co. LLC Sells 8,487 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Eventide Asset Management LLC Sells 40,548 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Bellevue Group AG - MarketBeat
Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options - sharewise.com
Seagate, Alnylam Are Among Six Companies Set to Join Nasdaq 100 - Bloomberg.com
Annual Changes to the Nasdaq-100 Index® - GlobeNewswire Inc.
How Good Is Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), When It Comes To ROE? - Yahoo Finance
Is It Too Late to Consider Alnylam Pharmaceuticals After Its Huge 2025 Share Price Surge? - simplywall.st
Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027 - BioSpace
Is Alnylam Pharmaceuticals Stock Built to Withstand More Downside? - Trefis
$73 Billion Non-Opioid Therapeutics Industry Assessment, - GlobeNewswire
$73 Billion Non-Opioid Therapeutics Industry Assessment, 2032 Featuring AbbVie, GlaxoSmithKline, Acorda Therapeutics, Allay Therapeutics, Alnylam Pharmaceuticals and Other Key Players - Yahoo Finance
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $508.00 - MarketBeat
WINTON GROUP Ltd Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam (ALNY) Announces $34.4M Convertible Notes Repurchase - GuruFocus
Alnylam Pharmaceuticals stock price target raised by Stifel to $508 - Investing.com
ALNY: Stifel Raises Price Target to $508, Maintains Buy Rating | ALNY Stock News - GuruFocus
Alnylam to repurchase $34.4 million of convertible notes - Investing.com
Alnylam announces partial repurchase of 1.00% convertible senior notes due 2027 - marketscreener.com
Alnylam Pharma Announces Convertible Notes Buyback - TipRanks
Alnylam Announces Partial Repurchase Of 1.00% Convertible Senior Notes Due 2027 - TradingView — Track All Markets
Alnylam Pharmaceuticals, Inc. Announces Partial Repurchase of Convertible Notes - TradingView — Track All Markets
Stifel maintains Alnylam Pharmaceuticals (ALNY) buy recommendation - MSN
United States Gene Therapy Market to Hit $6510.45 Million by 2033 - openPR.com
authID (NASDAQ: AUID) PrivacyKey named 2025 PayTech Awards Best Digital Trust Solution - Stock Titan
Thematics Asset Management Purchases New Shares in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Purchased by Investment Management Corp of Ontario - MarketBeat
1.74%
0.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):